In prostate cancer, combined treatment with AR inhibitors and chemotherapeutic agents has been tested in the clinic, but the efficacy of targeting multiple pathways mis-regulated in advanced prostate cancer has not been well studied [42]. This evidence concerns the gene AR and Familial prostate cancer.